Rankings
▼
Calendar
ESPR Q3 2024 Earnings — Esperion Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena
ESPR
Esperion Therapeutics, Inc.
$577M
Q3 2024 Earnings
Healthcare
Drug Manufacturers - Specialty & Generic
Income Statement
Revenue
$52M
+52.0% YoY
Gross Profit
$34M
66.5% margin
Operating Income
-$16M
-31.0% margin
Net Income
-$30M
-57.2% margin
EPS (Diluted)
$-0.15
QoQ Revenue Growth
-30.1%
Cash Flow
Operating Cash Flow
-$35M
Free Cash Flow
-$35M
Stock-Based Comp.
$3M
Balance Sheet
Total Assets
$314M
Total Liabilities
$684M
Stockholders' Equity
-$370M
Cash & Equivalents
$145M
Year-over-Year Comparison
Metric
Current
Year Ago
Change
Revenue
$52M
$34M
+52.0%
Gross Profit
$34M
$21M
+66.8%
Operating Income
-$16M
-$28M
+41.8%
Net Income
-$30M
-$41M
+28.4%
Revenue Segments
Product
$31M
60%
Collaboration Revenue
$21M
40%
← FY 2024
All Quarters
Q4 2024 →